Radiaction Medical Ltd. Secures Additional Patents in US and Japan – En-Route to Commercialization of its Radiation Shielding Technology

Radiaction Medical Ltd. (“Radication”), a medical device company, announced today that it was granted additional patents in the US and Japan, protecting key technological developments of its radiation shielding device.

Radiaction Medical, is revolutionizing radiation protection by providing full-body shielding to all medical personnel during fluoroscopy-guided procedures. Mounted on the C-Arm, it encapsulates the imaging beam and blocks the scattered radiation at its origin, creating a paradigm shift in medical staff radiation protection.  The system will initially be offered to the Interventional Cardiology (IC) and Electrophysiology (EP) markets, where physicians experience the highest radiation exposure.

Tested in a real-life clinical environments, the system demonstrated an entire room scattered radiation reduction performance of 91.2% in IC procedures and 93.3% in EP procedures. These rates are on par with the protection provided to the body’s core by lead aprons. Importantly, Radiaction Medical is protecting heads, arms, long bones and feet which are outside of the lead apron and are exposed and subjected to harmful cumulative radiation damage. This clinical experience also demonstrated high physician satisfaction with the integration into the clinical workflow.

Radiaction Medical has been expanding its IP assets continuously, protecting key technology developments for the radiation shielding device. The on-going advancements include various automation features, that allow smooth integration into clinical workflow and superior shielding of medical staff.

“We are pleased by the ongoing validation of our radiation shielding technology’s differentiation,” said Mr. Jonathan Yifat, CEO of Radiaction Medical. “As we are nearing commercialization, these patents strengthen our strategic IP assets and further our mission to provide a safe environment for healthcare teams in the interventional suite,” added Mr. Yifat.

In addition, the company successfully gained CE mark under the MDR with Emergo, paving the way for European initial installations at selected sites.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version